Cargando…

Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle

The gamma-herpesvirus Epstein-Barr virus (EBV) persists for life in infected individuals despite the presence of a strong immune response. During the lytic cycle of EBV many viral proteins are expressed, potentially allowing virally infected cells to be recognized and eliminated by CD8(+) T cells. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Croft, Nathan P., Shannon-Lowe, Claire, Bell, Andrew I., Horst, Daniëlle, Kremmer, Elisabeth, Ressing, Maaike E., Wiertz, Emmanuel J. H. J., Middeldorp, Jaap M., Rowe, Martin, Rickinson, Alan B., Hislop, Andrew D.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695766/
https://www.ncbi.nlm.nih.gov/pubmed/19557156
http://dx.doi.org/10.1371/journal.ppat.1000490
_version_ 1782168228115513344
author Croft, Nathan P.
Shannon-Lowe, Claire
Bell, Andrew I.
Horst, Daniëlle
Kremmer, Elisabeth
Ressing, Maaike E.
Wiertz, Emmanuel J. H. J.
Middeldorp, Jaap M.
Rowe, Martin
Rickinson, Alan B.
Hislop, Andrew D.
author_facet Croft, Nathan P.
Shannon-Lowe, Claire
Bell, Andrew I.
Horst, Daniëlle
Kremmer, Elisabeth
Ressing, Maaike E.
Wiertz, Emmanuel J. H. J.
Middeldorp, Jaap M.
Rowe, Martin
Rickinson, Alan B.
Hislop, Andrew D.
author_sort Croft, Nathan P.
collection PubMed
description The gamma-herpesvirus Epstein-Barr virus (EBV) persists for life in infected individuals despite the presence of a strong immune response. During the lytic cycle of EBV many viral proteins are expressed, potentially allowing virally infected cells to be recognized and eliminated by CD8(+) T cells. We have recently identified an immune evasion protein encoded by EBV, BNLF2a, which is expressed in early phase lytic replication and inhibits peptide- and ATP-binding functions of the transporter associated with antigen processing. Ectopic expression of BNLF2a causes decreased surface MHC class I expression and inhibits the presentation of indicator antigens to CD8(+) T cells. Here we sought to examine the influence of BNLF2a when expressed naturally during EBV lytic replication. We generated a BNLF2a-deleted recombinant EBV (ΔBNLF2a) and compared the ability of ΔBNLF2a and wild-type EBV-transformed B cell lines to be recognized by CD8(+) T cell clones specific for EBV-encoded immediate early, early and late lytic antigens. Epitopes derived from immediate early and early expressed proteins were better recognized when presented by ΔBNLF2a transformed cells compared to wild-type virus transformants. However, recognition of late antigens by CD8(+) T cells remained equally poor when presented by both wild-type and ΔBNLF2a cell targets. Analysis of BNLF2a and target protein expression kinetics showed that although BNLF2a is expressed during early phase replication, it is expressed at a time when there is an upregulation of immediate early proteins and initiation of early protein synthesis. Interestingly, BNLF2a protein expression was found to be lost by late lytic cycle yet ΔBNLF2a-transformed cells in late stage replication downregulated surface MHC class I to a similar extent as wild-type EBV-transformed cells. These data show that BNLF2a-mediated expression is stage-specific, affecting presentation of immediate early and early proteins, and that other evasion mechanisms operate later in the lytic cycle.
format Text
id pubmed-2695766
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-26957662009-06-26 Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle Croft, Nathan P. Shannon-Lowe, Claire Bell, Andrew I. Horst, Daniëlle Kremmer, Elisabeth Ressing, Maaike E. Wiertz, Emmanuel J. H. J. Middeldorp, Jaap M. Rowe, Martin Rickinson, Alan B. Hislop, Andrew D. PLoS Pathog Research Article The gamma-herpesvirus Epstein-Barr virus (EBV) persists for life in infected individuals despite the presence of a strong immune response. During the lytic cycle of EBV many viral proteins are expressed, potentially allowing virally infected cells to be recognized and eliminated by CD8(+) T cells. We have recently identified an immune evasion protein encoded by EBV, BNLF2a, which is expressed in early phase lytic replication and inhibits peptide- and ATP-binding functions of the transporter associated with antigen processing. Ectopic expression of BNLF2a causes decreased surface MHC class I expression and inhibits the presentation of indicator antigens to CD8(+) T cells. Here we sought to examine the influence of BNLF2a when expressed naturally during EBV lytic replication. We generated a BNLF2a-deleted recombinant EBV (ΔBNLF2a) and compared the ability of ΔBNLF2a and wild-type EBV-transformed B cell lines to be recognized by CD8(+) T cell clones specific for EBV-encoded immediate early, early and late lytic antigens. Epitopes derived from immediate early and early expressed proteins were better recognized when presented by ΔBNLF2a transformed cells compared to wild-type virus transformants. However, recognition of late antigens by CD8(+) T cells remained equally poor when presented by both wild-type and ΔBNLF2a cell targets. Analysis of BNLF2a and target protein expression kinetics showed that although BNLF2a is expressed during early phase replication, it is expressed at a time when there is an upregulation of immediate early proteins and initiation of early protein synthesis. Interestingly, BNLF2a protein expression was found to be lost by late lytic cycle yet ΔBNLF2a-transformed cells in late stage replication downregulated surface MHC class I to a similar extent as wild-type EBV-transformed cells. These data show that BNLF2a-mediated expression is stage-specific, affecting presentation of immediate early and early proteins, and that other evasion mechanisms operate later in the lytic cycle. Public Library of Science 2009-06-26 /pmc/articles/PMC2695766/ /pubmed/19557156 http://dx.doi.org/10.1371/journal.ppat.1000490 Text en Croft et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Croft, Nathan P.
Shannon-Lowe, Claire
Bell, Andrew I.
Horst, Daniëlle
Kremmer, Elisabeth
Ressing, Maaike E.
Wiertz, Emmanuel J. H. J.
Middeldorp, Jaap M.
Rowe, Martin
Rickinson, Alan B.
Hislop, Andrew D.
Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title_full Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title_fullStr Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title_full_unstemmed Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title_short Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle
title_sort stage-specific inhibition of mhc class i presentation by the epstein-barr virus bnlf2a protein during virus lytic cycle
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695766/
https://www.ncbi.nlm.nih.gov/pubmed/19557156
http://dx.doi.org/10.1371/journal.ppat.1000490
work_keys_str_mv AT croftnathanp stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT shannonloweclaire stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT bellandrewi stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT horstdanielle stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT kremmerelisabeth stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT ressingmaaikee stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT wiertzemmanueljhj stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT middeldorpjaapm stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT rowemartin stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT rickinsonalanb stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle
AT hislopandrewd stagespecificinhibitionofmhcclassipresentationbytheepsteinbarrvirusbnlf2aproteinduringviruslyticcycle